Back to mobile site

Buy Regenxbio (RGNX) for Breakup Story - Chardan Capital Markets

January 30, 2020 10:44 AM EST Send to a Friend
Chardan Capital Markets analyst Gbola Amusa reiterated a Buy rating and $150.00 price target on Regenxbio Inc. (NASDAQ: RGNX), telling ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login